前列地尔治疗早期糖尿病肾病疗效及安全性观察

目的：探讨前列地尔治疗糖尿病合并慢性肾病疗效及安全性，为临床治疗提供参考。方法选择2013年9月至2015年1月84例早期糖尿病合并慢性肾病患者，按照患者自愿原则分为观察组与对照组，观察组44例，对照组40例。对照组使用依帕司他联合吡格列酮治疗，观察组在对照组基础上联合前列地尔治疗，比较两组患者治疗有效率、血肌酐、尿素氮、尿清蛋白排泄率、C反应蛋白（CRP）、白细胞介素‐6（IL‐6）及不良反应。结果观察组治疗有效率为93．18％，明显高于对照组（80．00％），差异有统计学意义（χ2＝4．251，P＝0．005）；观察组与对照组治疗后CRP与IL‐6相比治疗前均有显著改善，差异有统计学意义（P＜0．05），观察组治疗后CRP（0．45±0．05）mg／L]与 IL‐6（0．72±0．11）μg／L]改善明显优于对照组（1．05±0．14）mg／L、（1．25±0．24）μg／L]，差异有统计学意义（P＜0．05）；观察组与对照组治疗后尿素氮、尿清蛋白排泄率、TNF‐α、内生肌酐清除率相比治疗前均有显著改善，差异有统计学意义（P＜0．05），观察组治疗后尿素氮、尿清蛋白排泄率、TNF‐α、内生肌酐清除率分别为（6．41±1．12）mmol／L、（41．12±4．46）μg／min、75．54±6．64）ng／L、（92．94±8．24）％，改善明显优于对照组（7．39±1．05）mmol／L、（91．48±7．31）mmol／L、（111．42±7．69）ng／L、（81．55±9．54）ng／L]，差异有统计学意义（P＜0．05）；观察组不良反应发生率为18．18％，对照组为17．50％，差异无统计学意义（ P＞0．05）。结论前列地尔治疗糖尿病合并慢性肾脏病疗效好，利于改善尿清蛋白排泄及炎症水平，安全性高，值得临床推广应用。

Observation on effect and safety of alprostadil in treatment of early diabetic kidney disease

Objective To investigate the effect and safety of alprostadil in the treatment of diabetes complicating chronic kid‐ney disease to provide reference for clinical treatment .Methods 84 cases of diabetes complicating chronic kidney disease in this hospital from September 2013 to January 2015 were selected and divided into the observation group(44 cases) and the control group (40 cases) according to the voluntary principle .The control group used the epalrestat treatment ,while the observation group was combined with using alprostadil on the basis of control group .The effective rate ,serum creatinine ,blood urea nitrogen(BUN) ,uri‐nary albumin excretion rate ,C‐reactive protein(CRP) ,IL‐6 levels and adverse reactions were compared between the two groups .Re‐sults The effective rate of the observation group was 93 .18% ,which was significantly higher than 80 .00% in the control group , the difference was statistically significant (χ2 =4 .251 ,P=0 .005);the CRP and IL‐6 levels after treatment in the observation group were improved ,the difference was statistically significant (P<0 .05);the CRP and IL‐6 levels after treatment in the observation group(0 .45 ± 0 .05)mg/L ,(0 .72 ± 0 .11)μg/L] were significantly superior than(1 .05 ± 0 .14)mg/L ,(1 .25 ± 0 .24)μg/L] in the control group ,the differences were statistically significant(P<0 .05);BUN ,urinary albumin excretion rate ,TNF‐αand endogenous creatinine clearance rate after treatment in the observation group were (6 .41 ± 1 .12)mmol/L ,(41 .12 ± 4 .46)μg/min ,(75 .54 ± 6 .64)ng/L and (92 .94 ± 8 .24)% ,which in the control group were (7 .39 ± 1 .05)mmol/L ,(91 .48 ± 7 .31)mmol/L ,(111 .42 ± 7 .69)ng/L and (81 .55 ± 9 .54)% respectively ,the improvement in the observation group was better than the control group ,the difference was statistically significant (P<0 .05);the occurrence rate of adverse reactions was 18 .18% in the observation group and 17 .50% in the control group ,showing the difference was not statistically significant (P>0 .05) .Conclusion Alprostadil in treating diabetes complicating chronic kidney disease has better effect ,conduces to improve the level of urinary albumin and inflammatory with high safety ,and is worthy of clinical promotion and application .